Video Library
Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases
In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.
Prof. Deepak L. Bhatt
First published: September 10, 2024
Video Library
European Society of Cardiology (ESC) Congress highlights 2024
Video highlights from the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2. Featuring faculty members Prof Stephen Nicholls, Prof Deepak Bhatt and Prof Yi-Heng Li, these clips provide invaluable insights and updates on cardiovascular research from ESC Congress 2024.
Prof Stephen Nicholls, Prof Yi-Heng Li
First published: August 30, 2024
Video Library
Therapeutic Management of Dyslipidaemia
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
Prof. Christopher Cannon
First published: August 1, 2024
Video Library
World Heart Federation Roadmap
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.
Prof. Christopher Cannon
First published: August 1, 2024
Video Library
Advancing Treatment for Atherosclerotic Cardiovascular Disease: Drug Therapies and Innovative Surgical Interventions
This video explores advancements in treating Atherosclerotic Cardiovascular Disease (ASCVD), highlighting novel drugs like olezarsen and inclisiran, surgical interventions for aortic stenosis, and the efficacy of percutaneous coronary interventions (PCIs). It encapsulates findings from the American College of Cardiology’s 73rd annual expo.
First published: July 3, 2024
Video Library
Highlights of “Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
This video summarizes Prof. Chiang’s discussion on ASCVD in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. The full discussion can be viewed here.
Prof. Chern-En Chiang
First published: June 28, 2024
Running time: 35 minutes, 49 seconds
00.16 Lp(a) structure and metabolism
01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases
02.38 Factors influencing Lp(a) level
03.35 Physiological functions of Lp(a)
04.12 Atherogenicity of Lp(a)
04.56 Clinical implication of Lp(a) elevation
05.25 Genetic variants associated with increased Lp(a) concentrations
05.44 Association between high Lp(a) level and risk of various cardiovascular diseases
07.43 Clinical implication of Lp(a) elevation at low LDL-C
08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors
09.40 Is reducing Lp(a) physiologically safe?
10.34 Strategies to lower Lp(a) level
11.57 Future directions in Lp(a) research
12.37 Summary
Video Library
Lp(a):What is it and its role in atherosclerosis
In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.
Prof. S. Lale Tokgözoğlu
First published: March 11, 2024
Video Library
Lipid measurements in the management of cardiovascular diseases
In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
First published: March 6, 2024
Video Library
The SANTORINI Study: Why Are Lipid Control Therapies Not Working?
In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.
First published: July 12, 2023
Video Library
Guidelines for Cardiovascular Risk Management in Women
This animated video highlights the importance of early identification and treatment of CVD risk factors in women.
Susan L. Ivey, Hattie Rees Hanley, Catrina Taylor, Eveline Stock, Nirali Vora, Jenny Woo, Sara Johnson, C. Noel Bairy Merz, Right Care Women's Cardiovascular Writing Group
First published: February 9, 2023